Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [13C]-aminopyrine breath test

Journal of Clinical Pharmacology

Volumn 52, Issue 3, 2012, Pages 432-439

  Kodaira, Chise ^a   Uchida, Shinya ^b   Yamade, Mihoko ^a   Nishino, Masafumi ^a   Ikuma, Mutsuhiro ^a   Namiki, Noriyuki ^b   Sugimoto, Mitsushige ^a   Watanabe, Hiroshi ^a   Hishida, Akira ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

13C aminopyrine breath test; CYP2C19; cytochrome P450; proton pump inhibitor

Indexed keywords

AMINOPHENAZONE; AMINOPHENAZONE C 13; CARBON 13; CARBON DIOXIDE; CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INFRARED SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMINOPYRINE; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CARBON ISOTOPES; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; OMEPRAZOLE; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84860189112     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010397728     Document Type: Article

References (29)

1. Satoh H, Inatomi N, Nagaya H, et al. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther. 1989 ; 248: 806-815
2. Nagaya H, Satoh H, Kubo K, Maki Y. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989 ; 248: 799-805
3. Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm. 1996 ; 53: 1401-1415
4. Furuta T, Futami H, Arai H, Hanai H, Kaneko E. Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. J Clin Gastroenterol. 1995 ; 20 (suppl 2). S107 - S111
5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008 ; 118: 1894-1909
6. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008 ; 52: 1502-1517
7. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008 ; 103: 2890-2907
8. McCarthy DM, McLaughlin TP, Griffis DL, Yazdani C. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther. 2003 ; 10: 330-340
9. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000 ; 14: 963-978
10. Giannini E, Romagnoli P, Fasoli A, et al. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. Am J Gastroenterol. 2000 ; 95: 2762-2767
11. Branch RA. Drugs as indicators of hepatic function. Hepatology. 1982 ; 2: 97-105
12. Irving CS, Schoeller DA, Nakamura KI, Baker AL, Klein PD. The aminopyrine breath test as a measure of liver function: a quantitative description of its metabolic basis in normal subjects. J Lab Clin Med. 1982 ; 100: 356-373
13. Mion F, Queneau PE, Rousseau M, Brazier JL, Paliard P, Minaire Y. Aminopyrine breath test: development of a 13C-breath test for quantitative assessment of liver function in humans. Hepatogastroenterology. 1995 ; 42: 931-938
14. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996 ; 60: 661-666
15. Kodaira C, Sugimoto M, Nishino M, et al. Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol. 2009 ; 65: 593-600
16. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther. 1995 ; 58: 155-164
17. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009 ; 301: 937-944
18. Chen BL, Chen Y, Tu JH, et al. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol. 2009 ; 49: 574-581
19. Schneider JF, Schoeller DA, Nemchausky B, Boyer JL, Klein P. Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clin Chim Acta. 1978 ; 84: 153-162
20. Fasoli A, Giannini E, Botta F, et al. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load: comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis. Hepatogastroenterology. 2000 ; 47: 234-238
21. Giannini E, Fasoli A, Chiarbonello B, et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2002 ; 16: 717-725
22. McColl KE, Kennerley P. Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis. 2002 ; 34: 461-467
23. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999 ; 13 (suppl 3). 27-36
24. Giannini EG, Malfatti F, Botta F, et al. Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test. Dig Dis Sci. 2005 ; 50: 1207-1213
25. Giannini EG, Savarino V, Testa R. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastroesophageal reflux disease. Dig Dis Sci. 2006 ; 51: 1602-1606
26. Henry DA, Somerville KW, Kitchingman G, Langman MJ. Omeprazole: effects on oxidative drug metabolism. Br J Clin Pharmacol. 1984 ; 18: 195-200
27. Diaz D, Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology. 1990 ; 99: 737-747
28. Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1992 ; 52: 170-180
29. Rost KL, Brosicke H, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology. 1994 ; 20: 1204-1212